Role of PET in gynecologic malignancy

Current Opinion in Oncology

Volumn 21, Issue 5, 2009, Pages 420-424

  Grigsby, Perry W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18 fluorodeoxyglucose; Gynecologic cancer; PET

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; TYROSINE C 11; UNCLASSIFIED DRUG;

ADRENAL TUMOR; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CURETTAGE; ENDOMETRIUM CANCER; GYNECOLOGIC CANCER; HUMAN; LAPAROSCOPY; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PAPANICOLAOU TEST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; TREATMENT RESPONSE; UTERINE CERVIX CANCER; UTERUS SARCOMA; VAGINA CARCINOMA; VULVA CANCER;

ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SARCOMA; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VULVAR NEOPLASMS;

EID: 69549088908     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832ec63f     Document Type: Review

References (29)

1. Lerman H, Metser U, Grisaru D, et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre and postmenopausal patients: assessment by PET/CT. J Nucl Med 2004; 45:266-271. (Pubitemid 47618647)
2. Grab D, Flock F, Stohr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000; 77:454-459. (Pubitemid 30368567)
3. Yamamoto Y, Oguri H, Yamada R, et al. Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography. Int J Gynecol Obstet 2008; 102:124-127. This study addresses the important issue of preoperatively determining the probability that a pelvic mass is benign versus malignant utilizing integrated FDG-PET/CT. The authors demonstrate a high diagnostic value in differentiating benign and malignant tumors.
4. Risum S, Høgdall C, Loft A, et al. The diagnostic value of PET/CT for primary ovarian cancer: a prospective study. Gynecol Oncol 2007; 105:145-149. (Pubitemid 46454333)
5. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001; 82:17-21. (Pubitemid 32634948)
6. Sironi S, Messa C, Mangili G, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 2004; 233:433-440. (Pubitemid 39423802)
7. Mangili G, Picchio M, Sironi S, et al. Integrated PET/CT as a first-line restaging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging 2007; 34:658-666. (Pubitemid 46669366)
8. Kitajima K, Murakami K, Yamasaki E, et al. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging 2008; 35:1912-1920.
9. Kidd EA, Grigsby PW. Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res 2008; 14:5236-5241. This study describes the metabolic heterogeneity of FDG metabolism found in cervical cancer and its importance in predicting survival outcome.
10. Wright JD, Dehdashti F, Herzog TJ, et al. Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer 2005; 104:2484-2491.
11. Rose PG, Adler LP, Rodriguez M, et al. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999; 17:41-45. (Pubitemid 29022376)
12. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001; 19:3745-3749. (Pubitemid 32844787)
13. Esthappan J, Chaudhari S, Santanam L, et al. Prospective clinical trial of positron emission tomography/computed tomography image-guided intensity-modulated radiation therapy for cervical carcinoma with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 2008; 72:1134-1139. Integrated FDG-PET/CT can be utilized for radiotherapy simulation and radiation treatment planning. In this study, the authors demonstrate the clinical use of integrated FDG-PET/CT in escalating the radiation dose to metastatic para-aortic lymph nodes.
14. Macdonald DM, Lin LL, Biehl K, et al. Combined intensity-modulated radiation therapy and brachytherapy in the treatment of cervical cancer. Int J Radiat Oncol Biol Phys 2008; 71:618-624.
15. Lin LL, Mutic S, Low DA, et al. Adaptive brachytherapy treatment planning for cervical cancer using FDG-PET. Int J Radiat Oncol Biol Phys 2007; 67:91-96. (Pubitemid 44959479)
16. Schwarz JK, Lin LL, Siegel BA, et al. 18-F-fluorodeoxyglucose-positron emission tomography evaluation of early metabolic response during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 2008; 72:1502-1507.
17. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007; 298:2289-2295. (Pubitemid 350146219)
18. Bodurka-Bevers D, Morris M, Eifel P, et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 2000; 78:187-193. (Pubitemid 30650352)
19. Brooks RA, Rader JS, Dehdashti F, et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol 2009; 112:104-109. The long-term follow-up of patients with cervical cancer can now be performed with FDG-PET/CT. Detection of early and asymptomatic recurrences of the disease can lead to early intervention resulting in long-term survival in selected patients.
20. Horowitz NS, Dehdashti F, Herzog TJ, et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004; 95:546-551. (Pubitemid 39592519)
21. Kitajima K, Murakami K, Yamasaki E, et al. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol 2009; 19:1529-1536.
22. Kitajima K, Murakami K, Yamasaki E, et al. Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer. Eur Radiol 2008; 18:2040-2047. This study demonstrates the utility of FDG-PET/CT in detecting recurrent cervical cancer.
23. Lin LL, Grigsby PW, Powell MA, Mutch DG. Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer. Int J Radiat Oncol Biol Phys 2005; 63:500-504.
24. Umesaki N, Tanaka T, Miyama M, et al. Positron emission tomography with 18F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol 2001; 80:372-377. (Pubitemid 32207538)
25. Ho K-C, Lai C-H, Wu T-I, et al. 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma. Eur J Nucl Med Mol Imaging 2008; 35:484-492. (Pubitemid 351661666)
26. Murakami M, Tsukada H, Shida M, et al. Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas. Int J Gynecol Cancer 2006; 16:854-860.
27. Cohn DE, Dehdashti F, Gibb RK, et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol 2002; 85:179-184. (Pubitemid 34304031)
28. De Hullu JA, Pruim J, Que TH, et al. Noninvasive detection of inguinofemoral lymph node metastases in squamous cell cancer of the vulva by L-[1-11C]-tyrosine positron emission tomography. Int J Gynecol Cancer 1999; 9:141-146. (Pubitemid 29220752)
29. Lamoreaux WT, Grigsby PW, Dehdashti F, et al. FDG-PET evaluation of vaginal carcinoma. Int J Radiat Oncol Biol Phys 2005; 62:733-737.